PL2855476T3 - Związki tetrahydropirazolopirymidynowe - Google Patents

Związki tetrahydropirazolopirymidynowe

Info

Publication number
PL2855476T3
PL2855476T3 PL13729184T PL13729184T PL2855476T3 PL 2855476 T3 PL2855476 T3 PL 2855476T3 PL 13729184 T PL13729184 T PL 13729184T PL 13729184 T PL13729184 T PL 13729184T PL 2855476 T3 PL2855476 T3 PL 2855476T3
Authority
PL
Poland
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
Prior art date
Application number
PL13729184T
Other languages
English (en)
Inventor
Roch Boivin
Eric Carlson
Atsushi Endo
Hans Hansen
Sally Ishizaka
Matthew MACKEY
Sridhar NARAYAN
Takashi Satoh
Shawn Schiller
Lynn D. Hawkins
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of PL2855476T3 publication Critical patent/PL2855476T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13729184T 2012-05-31 2013-05-31 Związki tetrahydropirazolopirymidynowe PL2855476T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
EP13729184.5A EP2855476B1 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
PL2855476T3 true PL2855476T3 (pl) 2019-02-28

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13729184T PL2855476T3 (pl) 2012-05-31 2013-05-31 Związki tetrahydropirazolopirymidynowe

Country Status (34)

Country Link
US (5) US9126999B2 (pl)
EP (1) EP2855476B1 (pl)
JP (2) JP6285918B2 (pl)
KR (2) KR102403007B1 (pl)
CN (2) CN107344941B (pl)
AR (1) AR091236A1 (pl)
AU (2) AU2013267204B8 (pl)
BR (1) BR112014030060B1 (pl)
CA (1) CA2874445C (pl)
CL (1) CL2014003278A1 (pl)
CY (1) CY1122692T1 (pl)
DK (1) DK2855476T3 (pl)
ES (1) ES2709119T3 (pl)
HR (1) HRP20181889T1 (pl)
HU (1) HUE040562T2 (pl)
IL (2) IL268013B2 (pl)
JO (1) JO3407B1 (pl)
LT (1) LT2855476T (pl)
MX (1) MX368455B (pl)
MY (1) MY172926A (pl)
NZ (1) NZ703459A (pl)
PE (2) PE20190973A1 (pl)
PH (2) PH12014502660B1 (pl)
PL (1) PL2855476T3 (pl)
PT (1) PT2855476T (pl)
RS (1) RS57977B1 (pl)
RU (2) RU2733959C2 (pl)
SG (1) SG11201407890VA (pl)
SI (1) SI2855476T1 (pl)
SM (1) SMT201800626T1 (pl)
TW (1) TWI572606B (pl)
UA (1) UA113440C2 (pl)
WO (1) WO2013181579A2 (pl)
ZA (1) ZA201409273B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3080124A1 (en) * 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
US10342795B2 (en) * 2014-03-27 2019-07-09 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
CN106573893B (zh) 2014-07-31 2020-06-09 巴斯夫欧洲公司 制备吡唑的方法
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
CA3187499A1 (en) 2015-05-11 2016-11-17 Eric George KLAUBER Process for preparing 4-amino-pyridazines
AU2015401326B2 (en) * 2015-07-03 2018-07-26 China Agricultural University Benzylhydrazone compounds and preparation method and application thereof
CA3010561C (en) * 2016-02-02 2024-04-16 Basf Se Catalytic hydrogenation process for preparing pyrazoles
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) * 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
JP2019524765A (ja) * 2016-08-02 2019-09-05 ソルヴェイ(ソシエテ アノニム) ピラゾールカルボン酸および誘導体の製造に有用なヒドラジニル化合物の製造、ヒドラジニル化合物ならびにその使用
KR102519535B1 (ko) * 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
CR20190119A (es) * 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
JP2020520379A (ja) * 2017-05-18 2020-07-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
BR112020011668A2 (pt) * 2017-12-15 2020-11-17 Bristol-Myers Squibb Company compostos de éter de indol substituído
FI3728252T3 (fi) * 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
JP7313354B2 (ja) * 2017-12-19 2023-07-24 ブリストル-マイヤーズ スクイブ カンパニー Tlr阻害剤として有用なアミド置換されたインドール化合物
BR112020012084A2 (pt) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos de indol substituído úteis como inibidores de tlr
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
US11299501B2 (en) 2017-12-20 2022-04-12 Bristol-Myers Squibb Company Diazaindole compounds
BR112020011984A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
EP3728198A1 (en) * 2017-12-22 2020-10-28 Solvay Sa Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof
JP2021507889A (ja) 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
US20210238136A1 (en) * 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
JP7367004B2 (ja) * 2018-09-06 2023-10-23 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のための新規のピラゾロビリジン化合物
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
JP2022506790A (ja) * 2018-11-09 2022-01-17 エフ.ホフマン-ラ ロシュ アーゲー 全身性エリテマトーデスを処置するためのTLR7~9アンタゴニストとしての、5-[6-[[3-(4,5,6,7-テトラヒドロピラゾロ[4,3-c]ピリジン-1-イル)アゼチジン-1-イル]メチル]モルホリン-4-イル]キノリン-8-カルボニトリル誘導体及び類似化合物
MX2021009439A (es) * 2019-02-07 2021-11-12 Beigene Ltd Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN114206872A (zh) * 2019-08-02 2022-03-18 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
JP2023502087A (ja) 2019-11-19 2023-01-20 エフ.ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロ-1H-ピロロ[1,2-a]ピラジン化合物
US20230097700A1 (en) * 2019-12-06 2023-03-30 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
GB202107932D0 (en) * 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
PL362320A1 (pl) 2000-12-06 2004-10-18 Aventis Pharma Deutschland Gmbh Pochodne guanidynowe i amidynowe jako inhibitory czynnika XA
DE50207103D1 (en) * 2001-03-14 2006-07-20 Gruenenthal Gmbh Substituierte pyrazolo- und thiazolopyrimidine als analgetika
AU2003219410A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
DE60317684T4 (de) 2002-06-19 2011-06-22 Janssen Pharmaceutica N.V., 2340 SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
CN1771231B (zh) * 2002-08-26 2011-05-25 武田药品工业株式会社 钙受体调节性化合物及其用途
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
WO2004111193A2 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
JP2007530417A (ja) 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
KR20070028400A (ko) 2004-05-04 2007-03-12 아카디아 파마슈티칼스 인코포레이티드 에스트로겐 리셉터에 활성을 갖는 화합물
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
RU2407736C2 (ru) 2004-10-12 2010-12-27 Декод Дженетикс Ехф Пери-замещенные арилсульфонамидные бициклические соединения, предназначенные для лечения окклюзионного заболевания артерий
JP2008520692A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
JP2008528510A (ja) 2005-01-20 2008-07-31 サートリス ファーマシューティカルズ, インコーポレイテッド 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
JPWO2006129587A1 (ja) 2005-05-30 2009-01-08 株式会社ジーンケア研究所 ピラゾロン誘導体を含有する医薬組成物
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007026950A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007102531A1 (ja) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited 併用薬
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007139795A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139816A2 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007146838A2 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
MX2009001036A (es) * 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AU2007360955A1 (en) 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. Enantiomerically enriched imidazoazepinone compounds
BRPI0820701A2 (pt) * 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2010051048A1 (en) 2008-02-20 2010-05-06 The Wistar Institute Microrna modulators and method for identifying and using the same
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2009111207A1 (en) 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
EP2300438A4 (en) 2008-06-11 2012-06-27 Merck Sharp & Dohme IMIDAZOLE DERIVATIVES AS FAAH INHIBITORS
AU2009257795A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of FAAH
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Hiv結合阻害剤としてのジケトピペリジン誘導体
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
WO2009158394A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
AU2009279874B2 (en) 2008-08-04 2015-02-12 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of FAAH
EP2312945A4 (en) 2008-08-13 2012-05-09 Merck Sharp & Dohme PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
JP5555236B2 (ja) 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター
EP2346335B1 (en) 2008-09-24 2018-11-14 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US20100120778A1 (en) 2008-11-07 2010-05-13 Wyeth Quinoxaline-based lxr modulators
CN102325754B (zh) 2009-01-19 2014-03-12 第一三共株式会社 含杂原子的环状化合物
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
US8901306B2 (en) 2009-03-02 2014-12-02 Stemsynergy Therapeutics, Inc. Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010141696A1 (en) 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20120316176A1 (en) 2009-12-22 2012-12-13 Deen Tulshian DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
RU2012136624A (ru) 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. Фармацевтические композиции для лечения боли и других показаний
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
CN103079558B (zh) 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
BR112012023971A2 (pt) 2010-04-22 2016-11-29 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto.
EP2977085A1 (en) 2010-04-23 2016-01-27 Kineta, Inc. Diarylpyridine anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−7−アミン誘導体を有効成分とするtlr9阻害剤
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
SG11201407919WA (en) 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]

Also Published As

Publication number Publication date
SG11201407890VA (en) 2014-12-30
PH12019500522A1 (en) 2020-11-04
US10640500B2 (en) 2020-05-05
HK1203498A1 (en) 2015-10-30
CN107344941B (zh) 2020-04-21
CA2874445C (en) 2022-06-21
CN107344941A (zh) 2017-11-14
IL235986A0 (en) 2015-02-01
CN104507939B (zh) 2017-07-25
US20130324547A1 (en) 2013-12-05
RS57977B1 (sr) 2019-01-31
JO3407B1 (ar) 2019-10-20
RU2018146532A3 (pl) 2019-06-21
CL2014003278A1 (es) 2015-06-12
CA2874445A1 (en) 2013-12-05
HRP20181889T1 (hr) 2019-01-11
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
US9850242B2 (en) 2017-12-26
MY172926A (en) 2019-12-14
BR112014030060A2 (pt) 2017-09-12
DK2855476T3 (en) 2018-12-17
MX2014014497A (es) 2015-06-02
HUE040562T2 (hu) 2019-03-28
AU2013267204A1 (en) 2015-01-29
KR20150016366A (ko) 2015-02-11
AU2013267204A8 (en) 2017-04-13
EP2855476A2 (en) 2015-04-08
WO2013181579A2 (en) 2013-12-05
RU2733959C2 (ru) 2020-10-08
US20160030430A1 (en) 2016-02-04
IL268013B2 (en) 2024-05-01
IL268013B1 (en) 2024-01-01
US20200347050A1 (en) 2020-11-05
AR091236A1 (es) 2015-01-21
AU2013267204B2 (en) 2017-04-06
WO2013181579A3 (en) 2014-03-27
CY1122692T1 (el) 2020-07-31
UA113440C2 (xx) 2017-01-25
IL268013A (en) 2019-09-26
PE20150220A1 (es) 2015-02-14
PH12014502660B1 (en) 2020-02-14
NZ703459A (en) 2016-09-30
KR20210076210A (ko) 2021-06-23
JP6285918B2 (ja) 2018-02-28
RU2014154397A (ru) 2016-07-27
AU2017204586B2 (en) 2018-11-08
AU2013267204B8 (en) 2017-04-13
US9126999B2 (en) 2015-09-08
BR112014030060B1 (pt) 2022-05-31
KR102268155B1 (ko) 2021-06-24
ZA201409273B (en) 2016-05-25
RU2018146532A (ru) 2019-01-31
SMT201800626T1 (it) 2019-01-11
RU2677291C2 (ru) 2019-01-16
KR102403007B1 (ko) 2022-05-31
IL235986B (en) 2019-11-28
MX368455B (es) 2019-10-03
CN104507939A (zh) 2015-04-08
JP6619829B2 (ja) 2019-12-11
LT2855476T (lt) 2019-01-10
US9446046B2 (en) 2016-09-20
PE20190973A1 (es) 2019-07-09
PH12014502660A1 (en) 2015-01-21
EP2855476B1 (en) 2018-09-05
ES2709119T3 (es) 2019-04-15
JP2015523981A (ja) 2015-08-20
TW201402575A (zh) 2014-01-16
SI2855476T1 (sl) 2018-12-31
AU2017204586A1 (en) 2017-07-27
TWI572606B (zh) 2017-03-01
US20160339032A1 (en) 2016-11-24
PT2855476T (pt) 2018-12-03
JP2018087221A (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
ZA201500778B (en) Compounds
SI2836495T1 (sl) Spojine tetrahidropirolotiazina
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218774D0 (en) Compounds
GB201218018D0 (en) Compounds
GB201217311D0 (en) Compounds
GB201217290D0 (en) Compounds
GB201217312D0 (en) Compounds